Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/48476
Conference/Presentation Title: Patterns of chemotherapy use for muscle-invasive bladder cancer at a single tertiary institution in Australia.
Authors: Kylie L.;Kevin C.;Matthew H.;Nieroshan R.;Paul M.;Scott D. ;Weranja R.
Monash Health Department(s): Urology
Institution: (Kylie, Kevin, Matthew, Nieroshan, Paul, Scott, Weranja) Department of Urology, Monash Health, Australia
Presentation/Conference Date: 18-Aug-2022
Copyright year: 2022
Publisher: Blackwell Publishing Ltd
Publication information: Asia-Pacific Journal of Clinical Oncology. Conference: 2022 ANZUP Annual Scientific Meeting. Adelaide, SA Australia. 18(Supplement 1) (pp 77), 2022. Date of Publication: July 2022.
Journal: Asia-Pacific Journal of Clinical Oncology
Abstract: INTRODUCTION AND OBJECTIVES: Although randomised studies demonstrate a survival benefit with neoadjuvant chemotherapy (NAC) prior to cystectomy (RC) in muscle-invasive bladder cancer (MIBC), concerns remain about delay in surgical treatment and progression in non-responders. There is no Australian data on patterns of NAC use prior to cystectomy. Our aim was to evaluate the patterns of NAC and adjuvant chemotherapy (AC) use for MIBC in a single tertiary centre. METHOD(S): Patients who had a histologic diagnosis of >= pT2 urothelial carcinoma and subsequent RC at our centre between 2011 and 2021 were retrospectively identified. Patient, chemotherapy and tumour data were collected and analysed. RESULT(S): Of a total of 120 patients, 70 had a RC for pT2+ bladder cancer. Of these patients, six (8.6%) received NAC prior to RC, 20 (28.6%) received AC and two (2.9%) received adjuvant radiotherapy. 19 patients (27.1%) developed metastases and 20 (28.6%) died at a median followup of 20.8 (IQR 7.3- 53.9) months. Of the patients who received NAC, the median time from diagnosis to RC was 3.8 months (IQR 2.1 -4.6). Of these, four (66.7%) had downstaging to pT1 disease at RC, one (16.7%) developed metastases and two (33%) died on follow-up. The median time from cystectomy to AC was 1.6 months and Gemcitabine and Cisplatin were most frequently used (55%). 26 patients out of 46 (56.5%) who were eligible for AC did not receive chemotherapy with the most common reason being patients being unfit (10.9%) and patients declining treatment (10.9%). Of the 20 patients who received AC, five (25%) developed metastases and six (30%) died following AC. There was no difference in progression-free survival or overall survival between those who received NAC and AC. CONCLUSION(S): Majority of patients undergoing RC received AC compared to NAC, reflecting real-world practice. Further studies on the determinants of real-world selection for NAC are needed.
Conference Name: 2022 ANZUP Annual Scientific Meeting
Conference Start Date: 2022-07-10
Conference End Date: 2022-07-12
Conference Location: Adelaide, SA, Australia
DOI: http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1111/ajco.13827
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/48476
Type: Conference Abstract
Subjects: adjuvant chemotherapy
adjuvant radiotherapy
bladder cancer
cancer adjuvant therapy
cancer patient
cancer surgery
cancer survival
cystectomy
histology
metastasis
muscle invasive bladder cancer
progression free survival
surgery
transitional cell carcinoma
cisplatin
gemcitabine
Type of Clinical Study or Trial: Observational study (cohort, case-control, cross sectional or survey)
Appears in Collections:Conference Abstracts

Show full item record

Page view(s)

188
checked on May 16, 2026

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.